CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Ideaya Biosciences Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Ideaya Biosciences Inc
7000 SHORELINE CT, SUITE 350
Phone: (302) 658-7581p:302 658-7581 SOUTH SAN FRANCISCO, CA  94080  United States Ticker: IDYAIDYA
Business Summary
IDEAYA Biosciences, Inc. is a medicine oncology company. The Company is engaged in the discovery, development, and commercialization of transformative therapies for cancer. Its product candidates focus on synthetic lethality and antibody-drug conjugates (ADCs) for molecularly defined solid tumor indications. Its product candidates include darovasertib (PKC), IDE397 (MAT2A), IDE849 (DLL3), IDE161 (PARG), IDE275 (Werner Helicase) and IDE705 (Pol Theta Helicase). Darovasertib is a clinical stage, potent and selective small molecule inhibitor of PKC, a protein kinase that functions downstream of the GTPases GNAQ and GNA11. IDE397 is an oral small molecule inhibitor of methionine adenosyl transferase 2a (MAT2A). IDE161 is an oral small molecule poly (ADP-ribose) glycohydrolase (PARG) inhibitor. IDE275 is an oral small molecule inhibitor of the helicase domain of the Werner protein (WRN), a RecQ enzyme involved in the maintenance of genome integrity.
(Source: Company's Website)

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
12/31/202512/31/2025YesYes---

Industries
SIC Code Description
2834 Pharmaceutical preparations
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Independent Chairman of the Board Terry J.Rosen 66 6/1/2023 1/1/2016
President, Chief Executive Officer, Director Yujiro S.Hata 51 6/1/2015 6/1/2015
Chief Financial Officer JoshuaBleharski 50 6/26/2025 6/26/2025
9 additional Officers and Directors records available in full report.

Business Names
Business Name
IDEAYA BIOSCIENCES
IDYA

General Information
Number of Employees: 145 (As of 12/31/2025)
Outstanding Shares: 87,814,027 (As of 2/13/2026)
Shareholders: 8
Stock Exchange: NASD
Federal Tax Id: 474268251
Fax Number: (302) 655-5049
Email Address: info@ideayabio.com


Copyright © 2026 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Saturday, April 11, 2026